Amantadine extended-release (ER) capsules (GOCOVRITM) are approved in the USA for the treatment of dyskinesia in people with Parkinson's Disease who are taking L-dopa. With a recommended dosage of 274 mg once daily at bedtime, the new formulation of amantadine allows a more gradual time to peak plasma amantadine concentration and higher drug concentrations in the morning and throughout the day, which is the time period when L-dopa induced dyskinesia (LID) is the most problematic.
For more information go to :https://www.rxlist.com/gocovri-drug.htm
After 13 weeks and 25 weeks amantadine ER capsules significantly improved L-dopa-induced dyskinesia (LID), while also increasing ON time without troublesome dyskinesia and reducing OFF time and ON time with troublesome dyskinesia from the morning and throughout the day. After 64 weeks patients previously treated with amantadine ER maintained their improvements.
Amantadine ER was generally well tolerated, with most of the adverse events (AEs) of amantadine ER being transient and mild or moderate in severity. The most common adverse events were treatment related and had an incidence of more than 15%.
Reference : CNS Drugs [2018] Aug 7 [Epub ahead of print] (J.Paik, S.J.Keam) Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/30088203
http://www.viartis.net/parkinsons.disease/news/180811.pdf
No comments:
Post a Comment